Erythropoietin a promising agent in the prevention of renal ischemia reperfusion injury

Mohammed Elshiekh, Mehri Kadkhodaee, Behjat Seifi

Abstract


Erythropoietin (EPO) is an essential growth factor, which stimulates red blood cell formation by targeting hematopoietic colony forming unit (CFU-E) in the bone marrow. Erythropoietin stimulating agents (ESAs) such as recombinant human EPO (rHuEPO) are created by recombinant DNA technology in cell culture which is widely used for the treatment of anemia in chronic kidney disease (CKD). The potential protective effects of EPO against ischemia reperfusion (IR) injury have become manifest in kidney IR injury model and kidney replacement therapy. In our review, we discuss the evidence upholding EPO as essential agent in kidney IR injury and discuss the potential pathways by which it may confer this specific protection.

 

Core tip
In recent years, several studies have shown that EPO diminishes tissue injury in many organs including kidneys, heart and brain by anti-apoptotic, anti-oxidative and pro-angiogenic effects. It has also anti-inflammatory actions which supports its essential protective role in renal IR injury. As a result of these activities EPO may have an important role in the future of medical sciences.

 

Citation: Elshiekh M, Kadkhodaee M, Seifi B. Erythropoietin a promising agent in the prevention of renal ischemia reperfusion injury. Ann Res Antioxid. 2017;2(2):e01.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.



ISSN: 2476-5511



Publish Free - Access Free

 

A Publication of Society of Diabetic Nephropathy Prevention

 

Annals of Research in Antioxidants follows

 

http://publicationethics.org/resources/flowcharts

Publisher

This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 by Annals of Research in Antioxidants (ARA)\

Society of Diabetic Nephropathy Prevention